Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Stem Cell Transplantation and Myeloablation

A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation

Leukemia volume 14, pages 1954–1959 (2000)Cite this article

Abstract

Busulfan has been previously only available in an oral formulation due to its poor water solubility. We report the results of a phase I study of multiple escalating doses of intravenous busulfan (Spartaject Busulfan, Orphan Europe, Paris, France) for myeloablation prior to stem cell transplantation (SCT) in 12 patients with chronic myeloid leukemia, acute myeloid leukemia or acute lymphocytic leukemia. One patient received allogeneic SCT; the other 11 patients received autologous SCT. The first six patients received i.v. busulfan diluted in 50 ml of 0.9% normal saline and the last six patients received busulfan in a 500-ml 5% dextrose solution. All patients experienced profound myelosuppression and all but one demonstrated hematopoietic engraftment. Toxicity was mild or moderate and there were no toxic deaths attributable to busulfan. Of note, there were no cases of veno-occlusive disease of the liver. Busulfan plasma concentrations were determined by gas chromatography with electron capture detection and showed little intra-patient variability. In most cases there was no significant difference between the first and last dose PK parameters. These data suggest that dose adjustment based on first dose PK data could allow uniformity of busulfan dosing for patients receiving SCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Demirer T, Buckner CD, Appelbaum F, Bensinger WI, Sanders J, Lambert K, Clift R, Fefer A, Storb R, Slattery JT . Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels Bone Marrow Transplant 1996 17: 491–495

    CAS  PubMed  Google Scholar 

  2. Hassan M, Ehrsson H, Ljungman P . Aspects concerning busulfan pharmacokinetics and bioavailability Leuk Lymphoma 1996 22: 395–407

    Article  CAS  PubMed  Google Scholar 

  3. Vassal G . Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls Anticancer Res 1994 14: 2363–2370

    CAS  PubMed  Google Scholar 

  4. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, Anasetti C, Bensinger WI, Fisher LD, Appelbaum FR . Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 1995 16: 31–42

    CAS  PubMed  Google Scholar 

  5. Pawlowska AB, Blazar BR, Angelucci E, Baronciani D, Shu XO, Bostrom B . Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia Bone Marrow Transplant 1997 20: 915–920

    Article  CAS  PubMed  Google Scholar 

  6. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin LS, Devine SM, Geller RB, Heffner LT, Hillyer CD, Holland HK, Winton EF, Saral R . Association of busulfan area under the curve with veno-occlusive disease following BMT Bone Marrow Transplant 1996 17: 225–230

    CAS  PubMed  Google Scholar 

  7. Slattery JT, Risler LJ . Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation Ther Drug Monit 1998 20: 543–549

    Article  CAS  PubMed  Google Scholar 

  8. Schuler US, Ehrsam M, Schneider A, Schmidt H, Deeg J, Ehninger G . Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation Bone Marrow Transplant 1998 22: 241–244

    Article  CAS  PubMed  Google Scholar 

  9. Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G . High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients Bone Marrow Transplant 1997 20: 909–913

    Article  CAS  PubMed  Google Scholar 

  10. Shaw PJ, Scharping CE, Brian RJ, Earl JW . Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia Blood 1994 84: 2357–2362

    CAS  PubMed  Google Scholar 

  11. Regazzi MB, Locatelli F, Buggia I, Bonetti F, Zecca M, Pregnolato M, Quaglini S . Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation Clin Pharmacol Ther 1993 54: 45–52

    Article  CAS  PubMed  Google Scholar 

  12. Vassal G, Koscielny S, Challine D, Valteau-Couanet D, Boland I, Deroussent A, Lemerle J, Gouyette A, Hartmann O . Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation Cancer Chemother Pharmacol 1996 37: 247–253

    Article  CAS  PubMed  Google Scholar 

  13. Quernin MH, Poonkuzhali B, Montes C, Krishnamoorthy R, Dennison D, Srivastava A, Vilmer E, Chandy M, Jacqz-Aigrain E . Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol J Chromatogr B Biomed Sci Appl 1998 709: 47–56

    Article  CAS  PubMed  Google Scholar 

  14. Olavarria E, Kanfer E, Szydlo R, O'Brien S, Craddock C, Apperley J, Goldman JM . High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single centre experience Br J Haematol 2000 108: 769–777

    Article  CAS  PubMed  Google Scholar 

  15. Buggia I, Locatelli F, Regazzi MB, Zecca M . Busulfan Ann Pharmacother 1994 28: 1055–1062

    Article  CAS  PubMed  Google Scholar 

  16. Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, Stary J, Wallin I, Kallberg N . Busulfan bioavailability Blood 1994 84: 2144–2150

    CAS  PubMed  Google Scholar 

  17. Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR, Slattery JT . The impact of obesity and disease on busulfan oral clearance in adults Blood 1999 93: 4436–4440

    CAS  PubMed  Google Scholar 

  18. Slattery JT, Risler LJ . Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation Ther Drug Monit 1998 20: 543–549

    Article  CAS  PubMed  Google Scholar 

  19. Schuler US, Schroer S, Kuhnle A, Blanz J, Mewes K, Kumbier I, Proksch B, Zeller KP, Ehninger G . Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994 14: 759–765

    CAS  PubMed  Google Scholar 

  20. Grochow LB . Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens Semin Oncol 1993 20: (Suppl. 4) 18–25

    CAS  PubMed  Google Scholar 

  21. Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS . Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy Cancer Chemother Pharmacol 1996 37: 401–408

    Article  CAS  PubMed  Google Scholar 

  22. Hassan Z, Nilsson C, Hassan M . Liposomal busulphan: bioavailability and effect on bone marrow in mice Bone Marrow Transplant 1998 22: 913–918

    Article  CAS  PubMed  Google Scholar 

  23. Ehninger G, Schuler U, Renner U, Ehrsam M, Zeller KP, Blanz J, Storb R, Deeg HJ . Use of a water-soluble busulfan formulation – pharmacokinetic studies in a canine model Blood 1995 85: 3247–3249

    CAS  PubMed  Google Scholar 

  24. Hassan M, Hassan Z, Nilsson C, Rehim MA, Kumlien S, Elfsson B, Kallberg N . Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration Cancer Chemother Pharmacol 1998 42: 471–478

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was sponsored by Orphan Europe.

Author information

Authors and Affiliations

  1. Department of Haematology, Hammersmith Hospital, ICSM, London, UK

    E Olavarria, A Eades, A Timms, C Craddock, E Kanfer, J Apperley & J Goldman

  2. Laboratory of Hematology, Huddinge University Hospital, Huddinge, Sweden

    M Hassan & C Nilsson

  3. Orphan Europe, Henley-on-Thames, UK

    J Matthews

Authors
  1. E Olavarria
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Eades
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Nilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Timms
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Matthews
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Craddock
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E Kanfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Apperley
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olavarria, E., Hassan, M., Eades, A. et al. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia 14, 1954–1959 (2000). https://doi.org/10.1038/sj.leu.2401921

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401921

Keywords

This article is cited by

Search

Advanced search

Quick links